GSK plc (GSK) Form 6-K — Jul 20, 2026
GSK plc announced that the European Medicines Agency has accepted a submission to update the label for Bexsero to include a single dose booster for individuals aged 10 years and older. The regulatory submission is supported by Phase 3b data demonstrating that a single booster dose effectively boosted immune responses in individuals aged 10 to 20 who were vaccinated during infancy.
Key figures
- Countries Registered
- 61
- Doses Distributed Since2015
- 138 million
- Men BSerogroup Prevalence EU
- 56%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.